BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3198216)

  • 1. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.
    Fichtinger-Schepman AM; Dijt FJ; Bedford P; van Oosterom AT; Hill BT; Berends F
    IARC Sci Publ; 1988; (89):321-8. PubMed ID: 3198216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).
    Fichtinger-Schepman AM; van Oosterom AT; Lohman PH; Berends F
    Cancer Res; 1987 Jun; 47(11):3000-4. PubMed ID: 3552211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
    Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts.
    Dijt FJ; Fichtinger-Schepman AM; Berends F; Reedijk J
    Cancer Res; 1988 Nov; 48(21):6058-62. PubMed ID: 3167856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
    Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ
    Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
    Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
    IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
    Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
    Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
    Chi KH; Kunugi KA; Kinsella TJ
    Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
    Meczes EL; Azim-Araghi A; Ottley CJ; Pearson DG; Tilby MJ
    Biochem Pharmacol; 2005 Dec; 70(12):1717-25. PubMed ID: 16259963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.
    Plooy AC; Fichtinger-Schepman AM; Schutte HH; van Dijk M; Lohman PH
    Carcinogenesis; 1985 Apr; 6(4):561-6. PubMed ID: 4039227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of cisplatin in blood compartments of cancer patients.
    Mustonen R; Hemminki K; Alhonen A; Hietanen P; Kiilunen M
    IARC Sci Publ; 1988; (89):329-32. PubMed ID: 3198217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential removal of DNA adducts derived from anti-diol epoxides of dibenzo[a,l]pyrene and benzo[a]pyrene in human cells.
    Dreij K; Seidel A; Jernström B
    Chem Res Toxicol; 2005 Apr; 18(4):655-64. PubMed ID: 15833025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
    Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
    Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
    Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
    J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.